

# Helena Jernberg-Wiklund

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6854878/publications.pdf>

Version: 2024-02-01

25  
papers

537  
citations

759055

12  
h-index

713332

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1099  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional loss of $\hat{\mu}$ leads to NF- $\hat{\mu}$ deregulation in aggressive chronic lymphocytic leukemia. Journal of Experimental Medicine, 2015, 212, 833-843.	4.2	85
2	Polycomb Target Genes Are Silenced in Multiple Myeloma. PLoS ONE, 2010, 5, e11483.	1.1	81
3	Epigenetics in multiple myeloma: From mechanisms to therapy. Seminars in Cancer Biology, 2018, 51, 101-115.	4.3	59
4	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget, 2016, 7, 6809-6823.	0.8	59
5	EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget, 2017, 8, 10213-10224.	0.8	47
6	A Role for the Chromatin Remodeling Factor <i>BAZ1A</i> in Neurodevelopment. Human Mutation, 2016, 37, 964-975.	1.1	29
7	Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. Cancer Gene Therapy, 2020, 27, 948-959.	2.2	28
8	Growth signals employ CGGBP1 to suppress transcription of Alu-SINEs. Cell Cycle, 2016, 15, 1558-1571.	1.3	20
9	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget, 2017, 8, 103731-103743.	0.8	19
10	Targeting EZH2 in Multiple Myeloma – Multifaceted Anti-Tumor Activity. Epigenomes, 2018, 2, 16.	0.8	18
11	Increased resistance to proteasome inhibitors in multiple myeloma mediated by <i>clAP2</i> - implications for a combinatorial treatment. Oncotarget, 2015, 6, 20621-20635.	0.8	17
12	The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA & Disease (Houston, Tex ), 2017, 4, .	1.0	14
13	Control of Apoptosis in Human Multiple Myeloma by Insulin-like Growth Factor I (IGF-I). Advances in Cancer Research, 2007, 97, 139-165.	1.9	12
14	CGGBP1 mitigates cytosine methylation at repetitive DNA sequences. BMC Genomics, 2015, 16, 390.	1.2	12
15	A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. Cell Death and Disease, 2021, 12, 167.	2.7	12
16	Multiple Myeloma Cell Lines. , 2002, , 81-155.		8
17	Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma. Upsala Journal of Medical Sciences, 2012, 117, 166-177.	0.4	4
18	Expression of Erythropoietin Receptor (EPO-R) and In Vitro Functional Effects of Epoetin in B-Cell Malignancies.. Blood, 2005, 106, 4278-4278.	0.6	4

#	ARTICLE	IF	CITATIONS
19	The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1833-1833.	0.6	3
20	One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. <i>Epigenomes</i> , 2021, 5, 22.	0.8	3
21	Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in Multiple Myeloma Cells Using Selective IGF-IR Tyrosine Kinase Inhibitors.. <i>Blood</i> , 2004, 104, 639-639.	0.6	2
22	MBRS-42. GMYC: A NOVEL INDUCIBLE TRANSGENIC MODEL OF GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i137-i137.	0.6	1
23	Selective Inhibition of Glycogen Synthase Kinase-3 by Facilitators of Insulin Response Promotes Proliferation and Survival in Multiple Myeloma Cells.. <i>Blood</i> , 2007, 110, 4789-4789.	0.6	0
24	ABT-737 Sensitizes B Cell Tumors for Killing by CD19-Retargeted T Cells,. <i>Blood</i> , 2011, 118, 4032-4032.	0.6	0
25	Combination of the IGF-1 Receptor Inhibitor Picropodophyllin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity. <i>Blood</i> , 2012, 120, 4010-4010.	0.6	0